Stratification Tool IDs Who Will Benefit From Adding Ezetimibe

This article originally appeared here.
Share this content:
Stratification Tool IDs Who Will Benefit From Adding Ezetimibe
Stratification Tool IDs Who Will Benefit From Adding Ezetimibe

THURSDAY, Feb. 23, 2017 (HealthDay News) -- For patients stabilized after acute coronary syndrome (ACS), a nine-point risk stratification tool can identify patients who will derive benefit from the addition of ezetimibe to statin therapy, according to a study published in the Feb. 28 issue of the Journal of the American College of Cardiology.

Erin A. Bohula, M.D., D.Phil., from the Brigham and Women's Hospital in Boston, and colleagues prospectively applied the nine-point Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention (TRS 2°P) stratification tool to 17,717 post-ACS patients randomized to ezetimibe and simvastatin or placebo and simvastatin in the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).

For the integer-based scheme, the researchers observed a strong graded correlation between the rate of cardiovascular (CV) death/myocardial infarction (MI)/ischemic cerebrovascular accident (iCVA), the trial composite end points, and the individual components (P trend < 0.0001 for each). At seven years, the absolute risk reduction in CV death/MI/iCVA was 6.3 percent for high-risk patients (defined by at least three risk indicators) taking ezetimibe/simvastatin, translating to a number-needed-to-treat of 16. The absolute risk reduction was 2.2 percent for intermediate-risk patients (two risk indicators). There was no benefit from addition of ezetimibe for low-risk patients (zero or one indicator).

"Atherothrombotic risk stratification using the TRS 2°P identifies high-risk patients who derive greatest benefit from the addition of ezetimibe to statin therapy for secondary prevention after ACS," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Merck, which funded IMPROVE-IT.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »